- Zoetis will acquire Neogen’s animal genomics business for $160 million, pending regulatory approval.
- The deal expands Zoetis’ Precision Animal Health capabilities across livestock and companion animals.
- Neogen’s genomics unit operates in more than 120 countries with five global laboratories.
- The acquisition strengthens Zoetis’ leadership in predictive analytics, individualized care, and data-driven livestock management.
- Closing is expected in the second half of 2026.
Zoetis Inc. has entered into a definitive agreement to acquire Neogen Corporation’s animal genomics business for $160 million, subject to customary closing adjustments. The transaction reinforces Zoetis’ long-term strategy to advance livestock innovation through genomics and further builds out its Precision Animal Health portfolio.
The acquisition brings together Zoetis’ global animal health expertise with Neogen’s established genomic technologies and data platforms, enhancing the company’s ability to deliver predictive insights and individualized animal care solutions worldwide.
Expanding Global Genomics Capabilities
Neogen’s animal genomics business serves customers in more than 120 countries and operates five laboratories located in the United States, Brazil, Australia, China, and the United Kingdom, along with an office in Canada. The business utilizes a comprehensive genotyping platform that includes fixed array and sequencing technologies, supported by advanced software tools designed to enable data-driven decision-making.
Recognized as a leader in U.S. beef and dairy genomics, Neogen’s technologies provide highly accurate and scalable genetic testing capabilities, offering deeper insights into animal health, productivity, and sustainability.
Advancing Predictive and Individualized Care
Jamie Brannan, Chief Commercial Officer at Zoetis, said the addition of Neogen’s genomics business enhances Zoetis’ commitment to innovation through data and technology.
“As we continue to grow our leading innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers,” Brannan said. “Together, we are shaping the future of animal health, empowering customers with the tools they need to support healthier animals and sustainable livestock production globally.”
Zoetis expects the transaction to close in the second half of calendar year 2026, subject to regulatory approvals and customary closing conditions. The company stated it is focused on ensuring a seamless integration process, maintaining continuity for employees and customers while building on Neogen’s established genomics legacy.
Company Background
Zoetis, with nearly 75 years in animal health, operates in more than 100 countries and develops medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions for veterinarians, livestock producers, and pet owners.
Neogen operates in more than 140 countries and provides solutions across food safety, livestock, and pet health and wellness markets, leveraging science and technology to support global food security and animal well-being.
Information sourced from the company’s press release.
